Matricelf Ltd
TASE:MTLF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Matricelf Ltd
Common Shares Outstanding
Matricelf Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Common Shares Outstanding
₪16.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Common Shares Outstanding
$57.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Common Shares Outstanding
$237.4m
|
CAGR 3-Years
134%
|
CAGR 5-Years
75%
|
CAGR 10-Years
91%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Common Shares Outstanding
$48.4m
|
CAGR 3-Years
28%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Common Shares Outstanding
$46.2m
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Common Shares Outstanding
$10m
|
CAGR 3-Years
28%
|
CAGR 5-Years
25%
|
CAGR 10-Years
26%
|
|
Matricelf Ltd
Glance View
Matricelf Ltd. engages in research and development of technology in the field of regenerative medicine. The firm operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The firm focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.
See Also
What is Matricelf Ltd's Common Shares Outstanding?
Common Shares Outstanding
16.2m
ILS
Based on the financial report for Dec 31, 2024, Matricelf Ltd's Common Shares Outstanding amounts to 16.2m ILS.
What is Matricelf Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 3Y
10%
Over the last year, the Common Shares Outstanding growth was 1%. The average annual Common Shares Outstanding growth rates for Matricelf Ltd have been 10% over the past three years .
